RT Journal Article
SR Electronic
T1 Manuscript title: Loss in the expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.29.20164681
DO 10.1101/2020.07.29.20164681
A1 Zeng, Qiang
A1 Huang, Gang
A1 Li, Yong-zhe
A1 Xu, Guoqiang
A1 Dong, Sheng-yong
A1 Zhong, Tian-yu
A1 Chen, Zong-tao
A1 Xu, Yang
YR 2020
UL http://medrxiv.org/content/early/2020/09/08/2020.07.29.20164681.abstract
AB Knowledge of the dynamic immunological characteristics of patients with coronavirus disease 2019 (COVID-19) is essential for clinicians to understand the progression of the disease. Our data showed that the immune system and function gradually remodeled and declined with age, starting from age 16 until age 91 in 25,239 healthy controls. An analysis of the relationship between the number of lymphocytes and age revealed that the lymphocyte and subset counts tended to decline with age significantly. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific immunity declined with age and was associated with survival time in fatal cases. Loss in the expansion of SARS-CoV-2-specific immunity could be expanded in vitro. The concurrent decline in SARS-CoV-2-specific cellular and humoral immunities and prolonged SARS-CoV-2 exposure predicted fatal outcomes. Our findings provide a basis for further analysis of SARS-CoV-2-specific immunity and understanding of the pathogenesis of fatal COVID-19 cases.HighlightsThe immune system and function gradually remodeled and declined with age.SARS-CoV-2-specific immunity declined with age in fatal cases.SARS-CoV-2-specific immunity was associated with survival time in fatal cases.Loss in the expansion of SARS-CoV-2-specific immunity could be expanded in vitro.A concurrent decline in SARS-CoV-2-specific cellular and humoral immunities and prolonged SARS-CoV-2 exposure predicted fatal outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Natural Science Foundation of China (Grant No. 81830052 and 81530053).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This case series was approved by the institutional ethics boardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have all data in the experiment.